Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic function.

J Cardiovasc Imaging · 2025 · PMC11727183 · PMID 39806504

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A meta-analysis on 11 randomized controlled trials showed a trend to decrease cardiac volume indices and improve of functional parameters in patients using SGLT2i, which were not statistically significant [ 19 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.